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Review ARTicles
citrulline and intestinal fatty acid-binding protein 
(i-FABP) have been increasingly studied since the turn 
of the millennium as potential biomarkers of intesti-
nal dysfunction [1–5]. citrulline has been proposed as 
a marker of enterocyte (dys)function, whereas i-FABP 
is thought to be a promising biomarker of intestinal 
cellular damage reflecting ischaemia.
The present narrative review summarizes patho-
physiological aspects and existing evidence evaluat-
ing clinical usage of these two biomarkers in criti-
cal illness based on explorative literature searches. 
Additionally, important details and pitfalls in sam-
pling, laboratory measurement and interpretation 
of values are discussed.
Citrulline as a marker of enteroCyte funCtion
Physiology and pathophysiology
citrulline (ciT) is a non-essential amino acid 
which is not present in proteins, but which is in-
timately involved in the urea cycle as an interme-
diary of both glutamine and arginine. citrulline is 
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produced from glutamine in the mitochondria of 
mature enterocytes. Although important in hepatic 
metabolism, its net production is almost exclusively 
in the small intestine, from where (as enterocytes 
lack argininosuccinate synthase) it is released into 
the portal circulation. Unless liver function is pro-
foundly disturbed, citrulline enters the systemic cir-
culation at a very similar concentration, only being 
removed in the kidney by conversion to arginine. 
There is sparse evidence that amino acid levels are 
increased in acute liver disease as a result of cata-
bolic breakdown of endogenous protein, from glu-
coneogenesis and from a failure of new hepatic pro-
tein synthesis. in animal models of acute liver failure 
plasma citrulline is elevated [6], this being most pro-
nounced in animals with hepatic encephalopathy. 
in humans with hepatic coma, dramatically high 
citrulline levels in cerebrospinal fluid have been ob-
served [7]. The changes in chronic liver disease are 
less pronounced, but circulating levels are high in 
animal models [8] and generally appear to be a little 
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Abstract
Currently there is no reliable tool available to monitor gastrointestinal function in the 
critically ill. Biomarkers are therefore of great interest in this field as the lack of monitor-
ing tools impedes any interventional studies. The potential biomarkers citrulline and 
intestinal fatty acid-binding protein (I-FABP) are the present focus. Targeted literature 
searches were undertaken for physiology and pathophysiology, sampling, measurement 
methods and clinical use of citrulline and I-FABP as biomarkers of intestinal function 
and injury. Physiology and pathophysiology, specific aspects of sampling and different 
laboratory assays are summarized and respective pitfalls outlined.
Studies in animals and patients outside the ICU support the rationale for these biomarkers. 
At the same time, evidence in critically ill patients is not yet convincing, several spe-
cific aspects need to be clarified, and methodology and interpretation to be refined. 
We conclude that there are good physiological rationales for citrulline as a marker of 
enterocyte function and for I-FABP as a marker of intestinal injury, but further studies 
are needed to clarify whether and how they could be used in daily practice in caring 
for critically ill patients. 
Key words: citrulline, critical care, intestinal fatty acid-binding protein, iFABP, 
FABP2, gastrointestinal function, gastrointestinal injury. 
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elevated in stable human disease [9, 10]. in acute on 
chronic disease – at any rate in alcoholic hepatitis – 
the levels may then fall [11].
The vast majority of citrulline released by the 
intestine is taken up in the proximal convoluted tu-
bules of the kidneys as a precursor for de novo argi-
nine synthesis [12]. Therefore expectedly, renal failure 
is associated with higher circulating citrulline levels 
[13–16] with the highest values observed in patients 
with end-stage renal failure. compared to controls 
with normal kidney function, citrulline levels are sig-
nificantly higher in patients with kidney dysfunction 
with a creatinine clearance of less than 50 ml min-1 
[14, 15]. similar to other amino acids, citrulline is 
removed with renal replacement therapy. citrulline 
plasma concentrations decrease more than 50% dur-
ing an intermittent haemodialysis session [13, 17]. 
little is known of citrulline loss in continuous renal 
replacement therapies, but it seems to be lower than 
that of other amino acids in paediatric patients treat-
ed with continuous venovenous haemodialysis [18].
Accordingly in patients with normal renal and 
hepatic function the circulating citrulline level may 
be considered a reproducible marker of entero-
cyte function. However, there are several steps in 
metabolism influencing its plasma concentration: 
1) availability of glutamine as a precursor of citrul-
line; 2) function of enterocytes; 3) liver function; 
4) metabolism in kidneys. 
This may be the reason why plasma citrulline 
levels, successfully used in the monitoring of pa-
tients following small bowel transplantation, are not 
yet of proven value for wider application in patients 
with acute severe illness with an unstable metabolic 
state. Unfortunately the concentrations of citrulline 
in blood do not follow a clear bimodal pattern so as 
to permit confident diagnosis or exclusion of intes-
tinal failure from the citrulline level alone. 
Urinary citrulline levels have been shown to cor-
relate with serum citrulline levels, but have not been 
investigated in critical illness [19].
Arguably the most important physiological role 
of citrulline is as a precursor for arginine, a nitric 
oxide (NO) donor. The importance of NO in sepsis 
and in critical care in general is acknowledged and 
supplementation with arginine has been considered 
logical in critically ill patients in order to raise nitric 
oxide levels and thus to combat oxidative damage. 
Although intracellular arginine concentrations are 
generally sufficient to saturate available NO syn-
thase (NOs), the addition of extrinsic arginine can 
nonetheless enhance NO production, in part via ac-
tivation of the cAT-2 arginine transporter, which is 
closely associated with NOs in cell membranes [20].
Therapeutic use of arginine has, after initial opti-
mism [21–24], not been proven to be beneficial in the 
critically ill. Notably, most of the studies used arginine 
as a part of a package of ‘immunonutrients’, making 
it difficult to determine a specific effect of this amino 
acid [25]. Nonetheless, evidence overtly in favour of 
parenteral arginine is lacking, making it difficult to 
dismiss the trials of combination immunotherapy 
that appear to show harm in a context where intra-
venous monotherapy proved fatal to dogs [26].
Despite this, the concept of the NO donor is still 
valid and more recently citrulline has received at-
tention as a source for arginine, it being known that, 
unlike arginine, which is largely extracted by the 
liver, citrulline passes on into the hepatic vein and 
thus into the systemic circulation and can arguably 
constitute a better arginine source than arginine it-
self [27, 28]. 
There is also reason to believe that citrulline 
might be of therapeutic potential in the critical care 
context. in vitro citrulline has positive effects on the 
immune response and reduces the effects of oxi-
dative stress [29]. in studies of trained athletes im-
provements in performance and enhanced recovery 
can be elicited [30]. An anabolic effect in sarcope-
nia has been shown in animals [31] and this is also 
supported by recent human studies [32]. citrulline 
as a therapeutic agent has been shown to be ben-
eficial in pulmonary hypertension, improving left 
ventricular ejection fraction, improving endothelial 
function [33] and in the rare MelAs syndrome (Mi-
tochondrial encephalomyopathy, lactic Acidosis, 
and stroke-like episodes syndrome) [34]. 
Sampling and measurement
in biological matrices, citrulline is most fre-
quently measured as part of an amino acid profile. 
However, time-efficient and comprehensive quan-
tification, of typically well in excess of the 21 pro-
teinogenic amino acids, from complex biological 
matrices, continues to be a challenge due to their 
poor chromophore and fluorophore response, zwit-
terion functionality and diversity. Different meth-
ods for analysing amino acid profiles have been 
proposed, utilising pre- and post-column derivati-
sation of either their amine or carboxyl functional 
groups with ninhydrin, o-phthalaldehyde, phenyl 
isothiocyanate, alkyl chloroformate, dansyl chloride 
or butanolic hydrochloric acid, and more recently 
methods requiring no derivatization and detection 
of the native analytes.
The dedicated amino acid analyser, employ-
ing ion exchange and ninhydrin post-column 
derivatization, is still considered the established 
standard methodology for clinical diagnostic use. 
A major disadvantage of this measurement proce-
dure is the long run time of typically 120 minutes 
and therefore the high total costs per sample [35]. 
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However, in recent years much effort has been spent 
on developing alternative robust high-throughput 
methods [36–39]. several analytical high perfor-
mance liquid chromatography (HPlc) pre-column 
derivatization methods have been developed for 
amino acid quantification, coupling liquid chroma-
tography with optical detection (ultra violet [Uv], 
fluorescence) or mass spectrometry (Ms) [39]. liquid 
chromatography mass spectrometry (lc-Ms) plays 
an important and increasing role as the detector of 
choice for HPlc, due to the selectivity which can 
distinguish analytes by their mass-to-charge ratio 
(m/z). lc-Ms/Ms has afforded gains of selectivity 
and sensitivity by utilising multiple reaction moni-
toring (MRM), whilst some investigators have uti-
lised the specificity of high resolution time of flight 
(ToF) mass spectrometry [36]. capillary electropho-
resis (ce) with or without derivatization addition of 
ion-pair reagents to HPlc mobile phases and hydro-
philic interaction chromatography (Hilic) [39] are 
other options to separate derivatized amino acids. 
Gas chromatography mass spectrometry (Gc-Ms), 
NMR and direct infusion have also been used for 
amino acid analysis [40]. No significant differences 
between blood samples collected into heparin or 
ethylenediaminetetraacetic acid (eDTA) or serum 
have been observed when stored for up to 7 days 
at 4°c [40]. For longer term storage, plasma samples 
precipitated with perchloric acid followed by neu-
tralisation with potassium carbonate prior to stor-
age at –80°c showed an undetectable reduction in 
concentration after 6 months and a 4.5% reduction 
after 5 years [41]. storage of frozen plasma without 
any additional preparation may however result in 
significant changes due to ongoing hydrolysis of 
proteins [42]. Available studies have used different 
handling of samples, possibly leading to different 
results. However, currently there is no consensus 
preferring one method over the other. Additionally 
to described methods, commercially available en-
zyme-linked immunosorbent assay (elisA) kits are 
available for the specific quantitation of citrulline. 
However, whilst requiring less expensive analytical 
instrumentation to perform the analysis, the re-
quirement to perform the analysis in duplicate can 
make this an expensive alternative for large studies.
Discussion of existing evidence
studies in patients with gastrointestinal diseases 
have shown that plasma citrulline levels are correlat-
ed with bowel length in short bowel syndrome pa-
tients but also with disease severity in enteropathies 
such as crohn’s or coeliac disease [1, 3, 5]. Moreover, 
citrulline levels may increase with treatment in co-
eliac disease [3, 5]. These observations suggest that 
citrulline may reflect enterocyte function which is 
not limited to enterocyte mass, and give a rationale 
to study citrulline in critically ill patients with rela-
tively unaffected enterocyte mass but impaired en-
terocyte function. This rationale is also supported by 
experimental and clinical data showing that citrul-
line levels decrease with toxic or radiation-induced 
injury to the small intestine [43–45].
importantly, assessment of post-absorptive lev-
els of citrulline is suggested in patients with gastro-
intestinal diseases [1, 46, 47], showing also a correla-
tion with absorption capacity measured with tracer 
ingestion methods [46]. in critical illness, specific 
assessment of a post-absorptive state is difficult, be-
cause patients are either not fed or receive enteral 
nutrition in a continuous manner.
A recent study in healthy men shows that plas-
ma citrulline levels increase during exercise in a nor-
mal hydrated state, but not during exercise when 
dehydrated [48].
To overcome the problem of elevated citrulline 
levels in renal failure patients (see also 2.1) adjust-
ment of the thresholds for acceptable citrulline has 
been suggested for patients with intestinal trans-
plant and chronic renal failure [14].
studies in critically ill patients have gener-
ally shown low citrulline levels [4, 49–54]. Piton de-
scribed initially (during the first 48 h after icU admis-
sion) decreasing plasma levels that recover towards 
the end of the first week [4]. 
several studies have shown an association be-
tween citrulline levels and the outcome of critical 
illness [4, 51, 52], whereas the direction of associa-
tion (causality) remains unclear. However, the most 
remarkable decreases in citrulline levels have been 
observed in the most severely ill patients, including 
those with septic shock or receiving catecholamines 
for another reason, having a poor neurological out-
come after cardiac arrest, and in those who ulti-
mately do not survive [4, 51, 52].
A few small studies have shown that low citrul-
line levels correlate with clinical signs of intestinal 
dysfunction [54, 55]. At the same time, citrulline 
levels were not found to correlate with small bowel 
capacity to absorb glucose in the critically ill [53] 
or with overall intestinal energy absorption capac-
ity [56]. A very small observation on metabolomics 
demonstrated that initially very low (compared to 
healthy) plasma citrulline levels increased during 
enteral nutrition but did not change during paren-
teral nutrition in critically ill patients [57].
Based on current evidence it is not possible to 
clearly conclude whether citrulline is suitable for 
specific monitoring of Gi (dys)function in critical ill-
ness. The main remaining questions are: 1) whether 
low levels largely reflect metabolic derangement 
related to a severe condition and not necessarily 
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absorption capacity in critical illness; 2) how to cre-
ate a scoring system (using citrulline as a marker of 
Gi function) in the absence of a gold standard for 
monitoring Gi function and absorption in critical ill-
ness; 3) how to deal with elevated citrulline levels 
due to renal dysfunction, often present in critical ill-
ness and also insufficiently described with currently 
available parameters (serum creatinine and urine 
output); 4) which other factors (e.g. fluid status, ad-
renergic state, concomitant diseases) influence ci-
trulline levels; 5) how to optimize rather complicated 
and expensive measurement of citrulline (see 2.2) for 
larger studies to answer the previous questions.
The theory about Gi dysfunction being a part 
and possibly also a motor of multiple organ dysfunc-
tion syndrome has been widely discussed [58, 59]. 
existing studies show that critical care patients 
demonstrating signs of Gi dysfunction are more 
severely ill than patients without Gi dysfunction 
[60–62]. However, clinical presentation of several 
concomitant Gi symptoms and/or feeding intoler-
ance during critical illness is independently associat-
ed with impaired outcome [60–62]. Despite several 
attempts, there is still no reliable tool to monitor Gi 
(dys)function in critical illness [59]. Descriptive grad-
ing of acute Gi injury has been proposed [63], but is 
1) based on subjective evaluation of Gi symptoms 
and tolerance of enteral nutrition, 2) not applicable 
retrospectively. Therefore, citrulline as a possible 
measurable and quantifiable marker for Gi dysfunc-
tion is of great interest.
Taken together, current evidence supports the 
hypothesis that citrulline may reflect enterocyte 
function in critical illness, but does not confirm its 
role as a marker of Gi (dys)function in daily clinical 
practice. Further studies are needed to establish 
whether citrulline could be used to test the effect 
of any interventions on Gi function or to help in 
guiding clinical decisions (e.g. on nutrition). citrul-
line dynamics need to be better related to clinical 
signs of Gi dysfunction but also studied together 
with methods evaluating absorption of different 
nutrients.
i-faBp as a marker of Cellular damage
Physiology and pathophysiology
i-FABP is a small (15 kDa) cytosolic protein that is 
exclusively present in mature epithelial cells of the 
small and large intestine. More specifically, i-FABP is 
found mainly in enterocytes of the duodenum and 
jejunum and, to a much lesser extent, in the ileum 
and colon [64]. At least 8 more proteins in the FABP 
family have been discovered and numbered – 
i-FABP is also known as FABP2 [65]. FABPs partici-
pate in the uptake, metabolism and transport of 
long-chain fatty acids [66].
in health, enterocytes undergo programmed 
apoptosis and are shed into the intestinal lumen 
with no extracellular release of intracellular con-
tents. Therefore, i-FABP plasma levels in apparently 
healthy humans have been found to be undetect-
able or very low [64, 67, 68] and reflect the natural 
enterocyte turnover. Due to their low molecular 
weight, fatty acid binding proteins are excreted 
rapidly (plasma half-life = 11 min for l-FABP [69]) 
unchanged via the kidneys.
Plasma i-FABP levels are expected to be elevated 
in renal dysfunction. A pilot study by Okada et al. 
demonstrated a twofold increase in i-FABP in pa-
tients with end-stage renal disease compared to 
controls with normal renal function [70]. Being 
a small water soluble protein, i-FABP was readily re-
moved during haemodialysis, yielding post-dialysis 
levels similar to controls [70]. More data are needed 
on the effects of renal failure and extracorporeal 
therapies on i-FABP levels to aid interpreting its lev-
els in critically ill patients. 
when enterocyte membrane integrity is brea-
ched, i-FABP is released into the extracellular space 
and enters the circulation. An additional mechanism 
of i-FABP uptake to the vasculature was proposed 
by schellekens et al.: after an ischaemic insult that 
has caused substantial necrosis and shedding of 
enterocytes from villi, causing a disruption in the 
gut barrier, i-FABP may be taken up from the lu-
men through an incomplete mucosal barrier [71]. 
This is suggested by their findings that after longer 
durations of ischaemia, i-FABP release still contin-
ues hours after cessation of ischaemia while there 
is histological proof of continued mucosal barrier 
disruption [71].
Mature enterocytes form the epithelium along 
and on top of intestinal villi, a location known to be 
highly susceptible to ischaemia. As such, i-FABP has 
for long been of interest as a marker of ischaemic 
intestinal epithelial damage. indeed, elevations in 
systemic i-FABP levels have been shown in various 
settings of intestinal ischaemia: in healthy adults un-
dergoing submaximal physical effort [68, 72]; after 
major but non-abdominal surgery [73–75]; trauma 
with and without abdominal lesions [67, 76]; after 
cardiac arrest [50, 52]; sepsis [77]; acute mesenteric 
ischaemia of both occlusive and non-occlusive 
types [78–80]. Previous research suggests that sys-
temic levels of i-FABP become elevated after minor 
ischaemic events with reversible injury of question-
able clinical significance as well as in cases with full-
thickness necrosis of the intestine and associated 
complications.
elevated i-FABP plasma levels have also been 
observed in conditions with other mechanisms of 
enterocyte damage, e.g. immune-mediated epithe-
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lial inflammation and villous atrophy in coeliac dis-
ease [81, 82] and the complex process of mucositis 
seen with some radiotherapy and chemotherapy 
schedules [83, 84].
Sampling and measurement
Measurement of i-FABP by enzyme-linked im-
munosorbent assay (elisA) is the most commonly 
used analytical technique. This assay involves the 
use of a monoclonal antibody specific for human 
i-FABP pre-coated onto the microtitre plate wells 
to detect endogenous i-FABP in samples, then by 
the addition of an enzyme-labelled polyclonal an-
tibody to capture and form a sandwich complex. 
Following a series of washing to remove any un-
bound antibody, a substrate solution is used to ac-
tivate colour development that is in proportion to 
the amount of bound i-FABP. The intensity of the 
colour (absorbance) is then measured by a spectro-
photometer at a specific wavelength. immunoas-
says are reliable, provided sufficient quality control 
measures are in place. The typical assay reproduc-
ibility (cv: coefficient of variation) is < 15%, which 
can be further improved by the use of a fully auto-
mated plate processor to increase throughput and 
minimise human error. However, the accuracy of 
i-FABP measurements has been reported to be sub-
optimal [85]; the quality of the antibody employed 
in immunoassays is highly dependent on its origi-
nating animal species and the purification process; 
variability in antibody production can affect the 
specificity of the antibody and reduce the ability of 
the assay to distinguish between the subtypes of 
FABP. For these reasons, i-FABP measurement is not 
routinely performed for diagnosis. commercial im-
munoassays can nonetheless provide adequate de-
tection of i-FABP in serum and urine. it is important 
to understand the limitations of the immunoassays 
employed, in particular their sensitivity and speci-
ficity, and to use them only for the predetermined 
purposes. Batch consistency can be ensured by 
using the same lot of antibody, with uniform pro-
cedures for operational processes, equipment and 
detection instruments. importantly, different mea-
surement kits with very different reference values 
have been used in the available studies of critically 
ill patients [86].
Summary of existing evidence
i-FABP plasma or serum levels have been studied 
in a very broad range of clinical conditions, summa-
rized below.
elevated i-FABP in plasma, serum or urine has 
been demonstrated in the presence of intestinal 
ischaemia including necrotizing enterocolitis in ne-
onates, and in several other abdominal pathologies 
(abdominal trauma, abdominal surgery, abdominal 
sepsis, acute pancreatitis, intestinal malignancies, 
coeliac disease, sclerosing cholangitis).
Intestinal ischaemia
Rapid and non-invasive diagnosis of intestinal 
ischaemia remains challenging, so there is great in-
terest in studying i-FABP in this context. 
in a human translational ischaemia-reperfusion 
model (resected jejunum studied in vitro), i-FABP re-
lease into blood stream occurred early during small 
bowel ischaemia [71]. i-FABP changes appear to oc-
cur very fast, an obvious increase occurring within 
30 minutes of ischaemia, declining within the next 
30 minutes of reperfusion, with full recovery within 
120 minutes [87].
such fast changes make it perfect for research, 
but possibly less perfect for clinical use, where the 
exact time of development of ischaemia cannot be 
captured. indeed, sufficient diagnostic value of se-
rum and urinary i-FABP was only confirmed in the 
early stages of mesenteric ischaemia in one study 
in 43 critically ill patients with suspected mesenteric 
ischaemia [88]. Moreover, it was hypothesized that if 
ischaemia is progressing transmurally and (re)perfu-
sion of the mucosa does not occur, i-FABP is possibly 
no longer flushed out, leading to ‘falsely’ low concen-
trations [88].
Another small study in patients with suspected 
acute mesenteric ischaemia demonstrated signifi-
cantly higher urinary i-FABP in patients with con-
firmed ischaemia (n = 13) vs. internal controls (ischae-
mia not confirmed, n = 5), whereas the difference in 
serum i-FABP was not significant [89]. 
in the third study comparing patients with con-
firmed vs suspected but not confirmed intestinal 
ischaemia, serum i-FABP levels were not significantly 
different between these two groups whereas lactate 
levels were [90].
There is increasing evidence suggesting i-FABP 
as a possible diagnostic tool in infants with sus-
pected necrotizing enterocolitis (Nec) [91–93]. 
The magnitude of the i-FABP response correlates 
with disease severity and the extent of surgical re-
section required [94], but perhaps surprisingly no 
association can be confirmed between i-FABP lev-
els and the incidence of bloodstream infection in 
these patients [95]. Two systematic reviews support 
a role for i-FABP in diagnosis of i-FABP, but recognize 
heterogeneity of data collection and relatively low 
study quality measures [96, 97].
Other abdominal conditions
Patients with intestinal malignancy are found 
to have elevated levels of i-FABP pre-operatively, 
and regardless of the underlying diagnosis major 
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abdominal surgery is responsible for its (further) 
elevation [98]. in patients with abdominal sepsis, 
significantly higher levels of i-FABP are found com-
pared to those with a comparable severity of sep-
sis caused by pneumonia [98]. Unfortunately this 
distinction was insufficiently binary to be clinically 
useful in differentiating abdominal from pulmonary 
infection [98]. This interpretation is also muddied 
somewhat by another study which showed that 
urinary i-FABP is predictive of disease severity and 
poorer survival in patients with pneumonia as the 
primary diagnosis [99]. 
Two studies of patients with abdominal trauma 
reached some similar conclusions, with clearly raised 
i-FABP levels in these patients compared to controls 
or those with non-abdominal injuries, and indeed 
a positive correlation with the day 0 and day 1 sOFA 
scores [100] and injury severity scores [76], but failed 
to show a correlation with sepsis or mortality [100].
in children with intestinal intussusception i-FABP 
levels are strongly associated with the presence of 
intestinal necrosis [92]. The authors were appropri-
ately reserved about the clinical value of this given 
that a cut-off of 1538 ng ml-1 yielded sensitivity and 
specificity of only 64% and 88% respectively. im-
portantly, the group of normal controls had a value 
of 478 ng ml-1, suggesting a major difference in cali-
bration from other investigators’ assays [101].
i-FABP is elevated in acute pancreatitis and sig-
nificantly more so in patients with more severe forms 
of acute pancreatitis (0.74 vs. 0.40 ng ml-1: P = 0.03), 
but this observation is insufficient alone to provide 
robust prognostic information [102]. The i-FABP lev-
els were however highly informative in the now in-
famous study of probiotics in acute pancreatitis, in 
which elevation was strongly associated with the lat-
er onset of bacteraemia, infected pancreatic necrosis 
and multi-organ failure (P values all under 0.05), and 
increased i-FABP appeared strongly linked to more 
extensive enterocyte damage and to more serious 
bacterial translocation [103].
in icU patients with acute gastrointestinal inju-
ry (AGi) [55] there was a close correlation between 
the severity of AGi and the level of i-FABP, whereas 
a prognostic association was not found [104]. Piton 
and capellier [105] suggested i-FAPB as a marker of 
intestinal mucosal damage to identify patients at 
the highest risk of bacterial translocation and the 
systemic inflammatory response syndrome.
Septic shock and endotoxaemia
elevated i-FABP was associated with significantly 
higher 28-day mortality in septic shock (P < 0.05), 
but the odds ratio of 1.036 suggests only very lim-
ited clinical value [106]. The authors propose how-
ever a threshold of 19 ng ml-1, above which their 
data predict a 28-day mortality of 29%, compared to 
only 2% with lower levels (P = 0.011) [106]. 
Positive correlations with endotoxin levels have 
been demonstrated for urinary i-FABP levels after 
successful resuscitation from cardiac arrest [50] and 
for plasma i-FABP levels in heat shock [107]. The uri-
nary i-FABP levels peaked 24 hours or more before 
those of the endotoxin, suggesting that there may 
be some predictive value [50].
in a study of 19 children with meningococcal 
septicaemia, patients in whom i-FABP returned to 
normal within 12 hours survived, whereas in non-
survivors i-FABP remained elevated through to the 
time of death [77]. 
Cardiovascular conditions
in cardiogenic shock or severe acute cardiac fail-
ure patients in the highest quartile (> 0.59 ng ml-1) 
of serum i-FABP on admission day had 2.5 times the 
30-day mortality of those in the lowest quartile, inde-
pendently of demographics or use of inotropes [108]. 
Moreover, if the initial level exceeded 10.2 ng ml-1 
the mortality rate was 88.9% [108]. This supports earlier 
data from Kitai et al. [109], who showed similar numeri-
cal linkage in acute decompensated cardiac failure but 
in whose patients the changes were not statistically 
significant. After cardiac surgery those with higher 
i-FABP had significantly more complications, includ-
ing higher frequencies of multiple organ dysfunction 
(P < 0.01), infectious complications (P < 0.01) and a lon-
ger icU stay (P < 0.01): in each case the median i-FABP 
was roughly twice as high in the adversely affected 
group [74]. i-FABP rose in all of a series of patients un-
dergoing aortic surgery (thoracic in 55 and exclusively 
abdominal in 25), and 4 patients with the highest levels 
died from intestinal ischaemia on day 2 or day 3 (sensi-
tivity and specificity both in excess of 98%) [80]. 
Other observations
Blood transfusion in premature infants is fol-
lowed by a reproducible rise in i-FABP [110], where-
as the mechanism remains unclear.
Taken together, despite some promising results, 
available studies have not been able to confirm re-
liability of i-FABP plasma, serum or urinary levels as 
a marker of intestinal injury in everyday clinical prac-
tice at the time. Different laboratory assays and refer-
ence levels (see also 3.2) are complicating synthesis 
of available evidence [86]. i-FABP is a promising bio-
marker, but future studies need to establish whether 
it will be usable as a marker of intestinal injury. 
summary of strengths and weaknesses
strengths and weaknesses of citrulline and i-FABP 
as biomarkers for gastrointestinal function/injury 
are summarized in Table 1.
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future studies
Unification of sample handling and measure-
ment methods is desirable to achieve comparable 
results in different studies. studies comparing dif-
ferent methods in repeated measurements should 
be undertaken to identify the methodology least 
prone to mistakes. studies with concomitant mea-
surement of mesenteric perfusion and Gi absorp-
tion should confirm the physiological rationale 
and measurement methods for these biomarkers. 
The role of renal dysfunction in dynamics of these 
biomarkers should be investigated in detail to allow 
correct interpretation of the results and selection of 
patients who may profit from measurements.
Thereafter, studies need to be undertaken to 
assess dynamics of biomarkers targeted to specific 
patient groups (e.g. critically ill patients with shock), 
specific events (e.g. Gi symptoms and/or complica-
tions) and interventions (e.g. enteral nutrition). Only 
then can cut-off values for specific events or inter-
ventions be validated. Taken together, there is still 
a long way for these biomarkers to advance to daily 
practice.
ConClusions
There is a good physiological rationale for ci-
trulline as a marker of enterocyte function and for 
i-FABP as a marker of intestinal injury. This rationale 
is supported by animal studies (mainly for i-FABP) 
and in patients outside the icU (mainly for citrul-
line), but less so in critically ill patients. in the light 
of the profound need for tools to assess Gi function 
and Gi injury in critically ill patients, these biomark-
ers deserve further investigations.
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